Elfin Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 7.05 M
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.42 Cr
- Satisfied Charges ₹ 18.50 Cr
- Revenue Growth 30.76%
- Profit Growth 37.07%
- Ebitda 26.66%
- Net Worth 5.18%
- Total Assets 25.28%
About Elfin Drugs
Elfin Drugs Private Limited (EDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 April 2005 and has a history of 19 years and ten months. Its registered office is in Rupnagar, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.05 M.
The company currently has active open charges totaling ₹20.42 Cr. The company has closed loans amounting to ₹18.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dilpreet Singh and Surinder Kaur serve as directors at the Company.
Company Details
- Location
Rupnagar, Punjab, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231PB2005PTC028300
- Company No.
028300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
What products or services does Elfin Drugs Private Limited offer?
Elfin Drugs Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Nutraceuticals & Dietary Supplements, Mineral Supplement, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Antacid Drugs, Common Disease Medicines, Pharmaceutical Medicine, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Elfin Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilpreet Singh  | Director | 25-Apr-2005 | Current |
| Surinder Kaur | Director | 19-Jun-2019 | Current |
Financial Performance of Elfin Drugs.
Elfin Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.76% increase. The company also saw a substantial improvement in profitability, with a 37.07% increase in profit. The company's net worth moved up by a moderate rise of 5.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elfin Drugs?
In 2023, Elfin Drugs had a public holding of 5.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elfin Pharma Private LimitedDilpreet Singh is a mutual person
Charges (Loans)
₹204.18 M
₹185.01 M
Charges Breakdown by Lending Institutions
- Bank Of India : 13.09 Cr
- Oriental Bank Of Commerce : 7.01 Cr
- Hdfc Bank Limited : 0.24 Cr
- Others : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Apr 2024 | Bank Of India | ₹13.09 Cr | Open |
| 04 Nov 2022 | Hdfc Bank Limited | ₹1.55 M | Open |
| 26 Mar 2021 | Hdfc Bank Limited | ₹0.90 M | Open |
| 01 Feb 2018 | Others | ₹0.70 M | Open |
| 18 Jan 2008 | Oriental Bank Of Commerce | ₹5.54 Cr | Open |
How Many Employees Work at Elfin Drugs?
Elfin Drugs has a workforce of 23 employees as of Sep 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elfin Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elfin Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
